Valuation: COMPASS Pathways plc

Market Cap 1.84B 1.61B 1.48B 1.37B 2.59B 175B 2.64B 17.69B 6.95B 86.23B 6.89B 6.74B 296B P/E 2026 *
-14.3x
P/E 2027 * -9.58x
Enterprise Value 1.41B 1.23B 1.14B 1.05B 2B 135B 2.03B 13.6B 5.34B 66.3B 5.3B 5.18B 228B EV / Sales 2026 *
-
EV / Sales 2027 * 21.7x
Free-Float
25.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: COMPASS Pathways plc

1 day+1.29%
1 week+7.24%
Current month-2.69%
1 month+24.84%
3 months+149.01%
6 months+96.71%
Current year+99.57%
1 week 11.56
Extreme 11.56
14.15
1 month 10.72
Extreme 10.724
15.4
Current year 4.88
Extreme 4.88
15.4
1 year 3.45
Extreme 3.45
15.4
3 years 2.25
Extreme 2.25
15.4
5 years 2.25
Extreme 2.25
49.52
10 years 2.25
Extreme 2.25
61.69
Manager TitleAgeSince
Chief Executive Officer 61 31/07/2022
Director of Finance/CFO 54 29/02/2024
Chief Tech/Sci/R&D Officer 66 30/04/2024
Director TitleAgeSince
Chairman 74 28/03/2024
Director/Board Member 69 31/03/2020
Director/Board Member 67 28/02/2021
Date Insider Type Main position Quantity % Market Cap.
05-26Free

Director

21,110 0.0220%
05-26Free

Director

21,110 0.0220%
05-26Free

Chairman

30,158 0.0314%
Change 5-day change 1-year change 3-year change Capi.($)
+1.29%+7.24%+270.16%+29.11% 1.84B
+0.58%+2.06%+2.92%+10.86% 50.44B
-1.50%-0.95%+388.81%+591.62% 40.63B
-0.80%+0.74%+25.35%-5.44% 34.88B
-1.19%-3.23%+18.19%+55.54% 33.67B
+1.21%-0.79%+4.46%+35.18% 26.29B
-1.93%+0.77% - - 17.11B
+0.11%-5.40%+62.85%+121.08% 15.29B
-8.52%-29.21%+38.93%+40.93% 10.62B
+0.23%-0.58%+13.76%+21.11% 13.74B
Average -1.02%-1.40%+91.71%+100.00% 24.45B
Weighted average by Cap. -0.70%+0.01%+86.27%+131.14%

Financials

2026 *2027 *
Net sales - 61.21M 53.54M 49.38M 45.61M 86.54M 5.84B 88M 590M 232M 2.88B 230M 225M 9.89B
Net income -100M -87.76M -80.95M -74.77M -142M -9.57B -144M -967M -380M -4.71B -377M -369M -16.21B -197M -172M -159M -147M -278M -18.78B -283M -1.9B -745M -9.25B -739M -723M -31.81B
Net Debt -424M -371M -342M -316M -600M -40.45B -610M -4.09B -1.61B -19.93B -1.59B -1.56B -68.5B -504M -441M -407M -376M -713M -48.1B -725M -4.86B -1.91B -23.69B -1.89B -1.85B -81.45B
Logo COMPASS Pathways plc
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.
Employees
156
Date Price Change Volume
10/07/26 US$13.77 +1.25% 2,803,426
09/07/26 US$13.60 -2.61% 3,023,427
08/07/26 US$13.97 +7.51% 7,532,720
07/07/26 US$12.99 +1.17% 14,233,189
06/07/26 US$12.84 -5.73% 3,202,169
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
13.60USD
Average target price
24.47USD
Spread / Average Target
+79.90%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CMPS Stock